China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026)
China Pharma Holdings (CPHI) posted Accounts Payables of $837108.0 for Q1 2026, down 6.06% on a QoQ basis from $891083.0 in Q4 2025, and down 61.08% year-over-year from $2.2 million in Q1 2025.
China Pharma Holdings (CPHI) Accounts Payables (2010 - 2026) Analysis & Trends
China Pharma Holdings' Accounts Payables history runs 17 years deep, the most recent figure standing at $837108.0 for Q1 2026.
- Quarterly Accounts Payables fell 61.08% year-over-year to $837108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $837108.0 (down 61.08% YoY) and the FY2025 annual result came in at $891083.0, down 59.18% from the prior year.
- Accounts Payables was $837108.0 for Q1 2026 at China Pharma Holdings, down from $891083.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.4 million in Q4 2022 and bottomed at $141036.0 in Q2 2024.
- A 5-year average of $975176.1 and a median of $831298.0 in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables sank 88.54% — and 2025, when it jumped 490.2%.
- China Pharma Holdings' Accounts Payables stood at $2.4 million in 2022, then plunged by 59.57% to $966420.0 in 2023, then surged by 125.88% to $2.2 million in 2024, then plunged by 59.18% to $891083.0 in 2025, then declined by 6.06% to $837108.0 in 2026.
- Business Quant data shows CPHI's Accounts Payables at $837108.0 in Q1 2026, $891083.0 in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 4.96 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.60 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 507.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 498.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1.67 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.75 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 773.00 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 372.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 837,108.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 837,108.00 |
| Dec 31, 2025 | 891,083.00 |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 530,729.00 |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 2.18 Mn |
| Sep 30, 2024 | 390,239.00 |
| Jun 30, 2024 | 141,036.00 |
| Mar 31, 2024 | 647,828.00 |
| Dec 31, 2023 | 966,420.00 |
| Sep 30, 2023 | 831,298.00 |
| Jun 30, 2023 | 414,084.00 |
| Mar 31, 2023 | 851,882.00 |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 361,192.00 |
| Jun 30, 2022 | 349,805.00 |
| Mar 31, 2022 | 338,414.00 |
| Dec 31, 2021 | 841,622.00 |
| Sep 30, 2021 | 1.73 Mn |
| Jun 30, 2021 | 3.05 Mn |